Davos Alzheimers Collaborative Inc
- Assets
- $14.1m
- Revenue
- $8.5m
- Investments
- $0.0
- Employees
- 0
- Location
- Wayne, PA
- Founding
- Data as of
- 12/2023
- EIN
- 86-1884515
Organization Overview
Davos Alzheimers Collaborative Inc is located in Wayne, PA. According to its NTEE Classification (G83) the organization is classified as: Alzheimers Disease, under the broad grouping of Voluntary Health Associations & Medical Disciplines and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Davos Alzheimers Collaborative Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Davos Alzheimers Collaborative Inc generated $8.5m in total revenue. This represents a relatively dramatic decline in revenue. Over the past 3 years, the organization has seen revenues fall by an average of (16.4%) each year. All expenses for the organization totaled $9.0m during the year ending 12/2023. You can explore the organizations financials more deeply in the financial statements section below.
Since 2021, Davos Alzheimers Collaborative Inc has awarded 13 individual grants totaling $3,449,547. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
SEE PART III LINE 1.
Describe the Organization's Program Activity:
Part 3 - Line 4a
HEALTHCARE SYSTEM PREPAREDNESS: DAC IS INVESTING TO TRANSFORM THE WAY HEALTHCARE SYSTEMS WORLDWIDE DETECT, DIAGNOSE AND TREAT ALZHEIMER'S. THE GOAL IS TO TAKE ADVANTAGE OF FUTURE INNOVATIONS TO IMPROVE THE QUALITY OF LIFE FOR PEOPLE EVERYWHERE. IN 2023, DAC CONTINUED TO ADVANCE 7 FLAGSHIP PROJECTS IN 6 COUNTRIES AS WELL AS SUPPORT AND MONITOR THE EXECUTION OF THE INITIAL GRANTS PROGRAM (12 GRANTS IN TOTAL). ADDITIONALLY, DAC DESIGNED OUR NEXT SET OF FLAGSHIP PROJECTS AND HAS BEEN WORKING CLOSELY WITH SITES ACROSS THE GLOBE TO LAUNCH THE PROGRAM IN 2024.
GLOBAL COHORTS - DAC IS BUILDING GLOBAL COHORTS TO ADVANCE UNDERSTANDING OF ALZHEIMER'S AMONG DIVERSE POPULATIONS. THIS DATA WILL PROVIDE THE FOUNDATION FOR IDENTIFYING NEW BIOMARKERS AND DEVELOPING TARGETED TREATMENTS THAT WORK FOR PEOPLE WORLDWIDE. IN 2023, DAC ADVANCED OUR RESEARCH AGENDA BY:- PROVIDING MULTI-YEAR FUNDING TO WORLDWIDE FINGERS TO ADAPT AND CUSTOMIZE THEIR RISK REDUCTION PROTOCOL IN OVER 60 COUNTRIES.- COMPLETING THE FIRST TWO PHASES OF A LONG-TERM PARTNERSHIP WITH AGA KHAN UNIVERSITY IN NAIROBI, KENYA THAT IS VALIDATING COGNITIVE TESTS, SALIVA BASED POLYGENIC RISK SCORES AND NOVEL DIGITAL COGNITIVE ASSESSMENTS IN LOCAL EAST AFRICAN POPULATION WITH THE GOAL OF CREATING A CLINICAL TRIAL READY COHORT FOR TESTING PHARMACOLOGICAL AND NON-PHARMACOLOGICAL INTERVENTIONS. - ACQUIRING BLOOD SAMPLES FROM FIRST 300 OF A 3000 PERSON HIGHLY CHARACTERIZED (PET, CLINICAL DX) SOUTH KOREAN COHORT AND ACCESS TO 1,000 BLOOD SAMPLES FROM A LONG-STANDING COHORT IN THE LATAM/CARIBBEAN REGION FOR FURTHER ANALYSIS BY DAC'S NETWORK OF DIAGNOSTIC AND PHARMA PARTNERS TO GENERATE AD BLOOD BIOMARKER VALIDATION DATA.- BUILDING AND MAINTAINING A ROBUST PIPELINE OF COMMITTED COHORTS WITH DETAILED PROPOSALS MOUS, RANGING FROM COLOMBIA TO TANZANIA TO RURAL TEXAS, TO TEST AND VALIDATE EARLY COGNITIVE IMPAIRMENT DETECTION TECHNOLOGIES WITH A FOCUS ON REMOTE, UNDERSERVED AREAS TO FIND TOOLS THAT CAN MORE EASILY SCALE GLOBALLY.
GLOBAL CLINICAL TRIALS - DAC IS MAINTAINING A NETWORK OF MORE THAN 30 EUROPEAN SITES ORGANIZED FOR ACCELERATING STUDIES AND IMPLEMENTING NOVEL TRIAL DESIGNS THAT IS BEING FUNDED BY A PHARMACEUTICAL COMPANY SPONSOR. DAC'S WORK THROUGH THE GLOBAL COHORT DEVELOPMENT PROGRAM SHOULD BE ABLE TO PROVIDE CLINICAL TRIAL READY POPULATIONS IN 2024 AND CREATE MORE OPPORTUNITIES FOR THE GLOBAL CLINICAL TRIAL PROGRAM.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
PDF Copies of 990 Filings
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
George Vradenburg Chair & President | OfficerTrustee | 20 | $0 |
Andrew Holzapfel COO (see Schedule O) | OfficerTrustee | 30 | $0 |
Freda Lewis Hall Treasurer | OfficerTrustee | 1 | $0 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
High Lantern Group Admin, Marketing, Pr, And It | 12/30/23 | $911,000 |
Wallace Res & Design Corp Healthcare Systems Prep. Mgr | 12/30/23 | $297,330 |
Bridgeable Proj. Mgmt For Lab & Consulting | 12/30/23 | $275,000 |
Faegre Drinker Legal Fees | 12/30/23 | $258,715 |
1point618 Inc Cohorts Program Support | 12/30/23 | $243,680 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $8,484,685 |
| Noncash contributions included in lines 1a–1f | $560,400 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $8,484,685 |
| Total Program Service Revenue | $0 |
| Investment income | $0 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $8,484,685 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $1,289,183 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $707,354 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $0 |
| Fees for services: Management | $911,000 |
| Fees for services: Legal | $315,382 |
| Fees for services: Accounting | $127,272 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $4,615,902 |
| Advertising and promotion | $636,629 |
| Office expenses | $1,577 |
| Information technology | $7,958 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $276,208 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $106,134 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $11,382 |
| All other expenses | $3,952 |
| Total functional expenses | $9,009,933 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $13,720,960 |
| Savings and temporary cash investments | $0 |
| Pledges and grants receivable | $100,000 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $246,178 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $14,067,138 |
| Accounts payable and accrued expenses | $1,186,024 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $1,186,024 |
| Net assets without donor restrictions | $12,177,430 |
| Net assets with donor restrictions | $703,684 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $14,067,138 |
Grants Awarded
Over the last fiscal year, Davos Alzheimers Collaborative Inc has awarded $1,289,183 in support to 6 organizations.
| Grant Recipient | Amount |
|---|---|
ADVOCATE AURORA HEALTH PURPOSE: SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE | $124,911 |
AVANT INSTITUTE PURPOSE: SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE | $23,084 |
INSTITUTE FOR HEALTHCARE IMPROVEMENT PURPOSE: SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE | $224,012 |
PHYSICIAN ASSISTANT FOUNDATION OF THE AMERICAN ACADEMY OF PHYSICIAN PURPOSE: SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE | $404,676 |
TRUSTEES OF BOSTON UNIVERSITY PURPOSE: SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE | $500,000 |
BOSTON UNIVERSITY'S SCHOOL OF MEDICINE ANATOMY & NEUROBIOLOGY DEPARTMENT PURPOSE: SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE | $12,500 |